COG AALL1122: A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66,971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Print this page

COG AALL1122: A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66,971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

1. To Compare the 3 year survival of historical chemotherapy to dasatinib + chemotherapy
2. To determine safety and efficacy of adding dasatinib to chemotherapy regimens for leukemia
3. To determine effect of dasatinib on MRD levels in pediatric patients with Philadelphia Positive Acute Lymphoblastic Leukemia

Protocol Number111108
Principal InvestigatorRichard Drachtman
PhasePhase II
ScopeNational
Applicable Disease SitesAny Site
Therapies InvolvedChemotherapy multiple agents systemic
Drugs InvolvedDASATANIB
Participating InstitutionsRutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.